Washington Roundup

May 2013
BioWorld Today;5/15/2013, Vol. 24 Issue 93, p2
This section offers U.S. medical news briefs including the effect of the lack of standards from the Office of the U.S. Global AIDS Coordinator (OGAC) for Acquired Immunodefficency Disease (AIDS) treatment programs, the proposed guideline revision from the Office of Biotechnology Activities of the National Institutes of Health and the clarification of the Food and Drug Administration (FDA) on the 2011 draft guidance on pharmaepidemiologic safety studies.


Related Articles

  • AHF Asks 'What's Rotten at FDA?' in New Politico Playbook Ads.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article reports on an advocacy campaign started by the company AHF to target decision of the U.S. Food and Drug Administration (FDA). According to AHF, fast track review has been granted by FDA for application of Gilead Sciences Inc. which supports the use of drug for acquired immune...

  • FDA goes after illegal Cipro Web sites. Dickinson, James G. // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p22 

    Reports on the issuance of warning letters to foreign Web site operators selling illegal generic ciprofloxacin in the U.S. Protection to the public from harmful drugs; Inability of the Food and Drugs Administration to determine the specification of the drugs marketed by the Web sites.

  • Drug Safety Concerns Shape Manufacturing Policy. Wechsler, Jill // Pharmaceutical Technology Europe;Mar2002, Vol. 14 Issue 3, p13 

    Reports on the move of the U.S. Food and Drug Administration to improve processes for evaluating the risk factors in new drug candidates and for tracking and evaluating adverse events once a product is on the market. Effect of the campaign of the agency on the manufacturing process of the...

  • Drug Safety Alerts Almost Double. J. G. D. // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p32 

    The article focuses on a report released by the U.S. Food and Drug Administration (FDA) which reflects the increase of drug safety alerts in the country in 2011.

  • Drug safety provisions in US and Europe outshine Canada. Silversides, Ann // CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE23 

    The article reports that new drug safety provisions are earning profits in the U.S. and Europe but the legislation to introduce new regulations in Canada are getting weakened. It is stated that U.S. Food and Drug Administration (FDA) is taking drug safety to a higher level and several new...

  • FDA targets Rx postmarketing.  // Drug Topics;11/22/2004, Vol. 148 Issue 22, p8 

    Reports that the United States Food and Drug Administration has directed its Center for Drug Evaluation and Research to strengthen its postmarketing safety program.

  • FDA Launches Mini-Sentinel Pilot.  // BioWorld Today;8/25/2011, Vol. 22 Issue 165, p6 

    This article reports on the launch of the Mini-Sentinel safety pilot program by the U.S. Food and Drug Administration (FDA) in 2011.

  • Safer drug supply requires update to our regulation. Benson, Patricia; Coukell, Allan // Hill;9/21/2011, Vol. 18 Issue 128, pS:10 

    The article reports on the concerns facing the U.S. Food and Drug Administration (FDA) over lax inspection on medicines made outside the country as it would take the agency longer time to visit and assess all foreign facilities that supply drugs and pharmaceutical ingredients.

  • What More Do You Need? Auerbach, Michael // Pharmaceutical Processing;Sep2008, Vol. 23 Issue 9, p6 

    The author reflects on the posting of the U.S. Food and Drug Administration (FDA) on its Web site regarding certain drugs that are being evaluated for potential safety issues. He states that the incarnation of the information provided by the agency is rather sparse. He believes that the FDA will...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics